These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24659838)

  • 1. Landmark Estimation of Survival and Treatment Effect in a Randomized Clinical Trial.
    Parast L; Tian L; Cai T
    J Am Stat Assoc; 2014 Jan; 109(505):384-394. PubMed ID: 24659838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landmark estimation of survival and treatment effects in observational studies.
    Parast L; Griffin BA
    Lifetime Data Anal; 2017 Apr; 23(2):161-182. PubMed ID: 26880366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFICIENT AND ROBUST ESTIMATION OF
    Zheng Y; Lu T; Cai T
    Stat Sin; 2021; 31():1531-1547. PubMed ID: 38075983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landmark Prediction of Long Term Survival Incorporating Short Term Event Time Information.
    Parast L; Cheng SC; Cai T
    J Am Stat Assoc; 2012; 107(500):1492-1501. PubMed ID: 23293405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-supervised calibration of noisy event risk (SCANER) with electronic health records.
    Hong C; Liang L; Yuan Q; Cho K; Liao KP; Pencina MJ; Christiani DC; Cai T
    J Biomed Inform; 2023 Aug; 144():104425. PubMed ID: 37331495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented estimation for t-year survival with censored regression models.
    Zheng Y; Cai T
    Biometrics; 2017 Dec; 73(4):1169-1178. PubMed ID: 28294286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
    Graham NM; Hoover DR; Park LP; Stein DS; Phair JP; Mellors JW; Detels R; Saah AJ
    Ann Intern Med; 1996 Jun; 124(12):1031-8. PubMed ID: 8633816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies.
    Wang X; Bai F; Pang H; George SL
    J Biopharm Stat; 2019; 29(4):592-605. PubMed ID: 31286838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An improved method for the effect estimation of the intermediate event on the outcome based on the susceptible pre-identification.
    Hu H; Wang L; Li C; Ge W; Xia J
    BMC Med Res Methodol; 2021 Sep; 21(1):192. PubMed ID: 34548029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.
    Díaz I; Colantuoni E; Hanley DF; Rosenblum M
    Lifetime Data Anal; 2019 Jul; 25(3):439-468. PubMed ID: 29492746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient Estimation of Semiparametric Transformation Models for the Cumulative Incidence of Competing Risks.
    Mao L; Lin DY
    J R Stat Soc Series B Stat Methodol; 2017 Mar; 79(2):573-587. PubMed ID: 28239261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiparametric methods for multistate survival models in randomised trials.
    Hudson HM; Lô SN; Simes RJ; Tonkin AM; Heritier S
    Stat Med; 2014 May; 33(10):1621-45. PubMed ID: 24338893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive-multiplicative hazards regression models for interval-censored semi-competing risks data with missing intermediate events.
    Kim J; Kim J; Kim SW
    BMC Med Res Methodol; 2019 Mar; 19(1):49. PubMed ID: 30841923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing semi-competing risks data with missing cause of informative terminal event.
    Zhou R; Zhu H; Bondy M; Ning J
    Stat Med; 2017 Feb; 36(5):738-753. PubMed ID: 27813148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting disease risks by matching quantiles estimation for censored data.
    Wu P; Liang BS; Xia YF; Tong XW
    Math Biosci Eng; 2020 Jun; 17(5):4544-4562. PubMed ID: 33120518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials.
    Zhang M
    Lifetime Data Anal; 2015 Jan; 21(1):119-37. PubMed ID: 24522498
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.